News

The required regulatory documents for the merger were approved by the New York State Attorney General on May 20, 2015. The combined entity, which will carry on the

The acquisition brings to Biota AP611074, a patented, direct-acting antiviral in clinical development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent

The open-label, single-arm, Phase 2 study is a thorough PK/PD assessment designed to: (1) measure the effects of CPX-351 on cardiac repolarization following the first induction cycle of

The Rapporteur (from Portugal) and Co-Rapporteur (from the United Kingdom) are the two appointed members of the Committee for Medicinal Products for Human Use (CHMP) who would lead

The company’s latest report* states that the global pharmaceutical industry is currently being confronted with intensified obstacles along the path to new product commercialization, with pricing and reimbursement

The Boston/Cambridge, Massachusetts area, and Zurich, Switzerland will serve as VBU’s global hubs for the vaccine business outside of Japan. VBU will maintain regional hubs in Singapore and

Trailing twelve-month sales for the product are $30 million, according to IMS, with three current competitors. ANI expects to begin shipping to its customers shortly. Arthur S. Przybyl,

Key components of the agreement include:– A new company, Kanyos Bio, Inc. ("Kanyos", location: Cambridge, MA), has been created to develop clinical candidates in the two selected indications,

The decision followed the Positive Opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on March 26 2015 and is applicable to all 28 European